

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/518,098	03/03/2000	Leland Shapiro	114232.107 5420	
27160	7590 07/28/2004		EXAMINER	
PATENT ADMINSTRATOR KATTEN MUCHIN ZAVIS ROSENMAN			LUKTON, DAVID	
525 WEST MONROE STREET			ART UNIT	PAPER NUMBER
SUITE 1600			1653	
CHICAGO, IL 60661-3693			DATE MAILED: 07/28/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>						
	Application No.	Applicant(s)				
Office Action Summers	09/518,098	SHAPIRO, LELAND				
Office Action Summary	Examiner	Art Unit				
	David Lukton	1653				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 28 Ju	ılv 2003.					
·	action is non-final.					
<i>'</i>		secution as to the merits is				
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 1-48 and 50-52 is/are pending in the application.						
4a) Of the above claim(s) 1-39,41-45,48 and 50-52 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>40,46 and 47</u> is/are rejected. 7)□ Claim(s) is/are objected to.						
8) Claim(s) are subjected to.						
· · · · · · · · · · · · · · · · · · ·	ciccion requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 						
Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	, , , ,	d.				
·						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) ☐ Notice of Informal Pa 6) ☐ Other:	atent Application (PTO-152)				
· · · · · · · · · · · · · · · · · · ·						

Pursuant to the directives of the response filed 7/28/03, claims 40 and 46 have been amended, and claim 49 cancelled. Claims 1-48 and 50-52 remain pending. Claims 40, 46 and 47 are examined in this Office action; claims 1-39, 41-45, 48, 50-52 remain withdrawn from consideration.

 \Diamond

The following is a quotation of the first paragraph of 35 U.S.C. §112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 40, 46, 47 are rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 40 and 46 recite that the compound which exhibits AAT-like activity "comprises" CE-2072. This is not supported by the specification as filed. The claims also recite that the compound which exhibits AAT-like activity comprises a "derivative" of CE-2072. This is also not supported by the specification as filed. Applicants are requested to point to the location in the text where they believe that descriptive support can be found.

 \Diamond

Claims 40, 46, 47 are rejected under 35 U.S.C. §112 second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Each of claims 40 and 46 recite that a compound can exhibit an activity which is somehow "like" that of α 1-antitrypsin. This renders the claims indefinite as to the manner in which and the extent to which, the compound must resemble α 1-antitrypsin.

*

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber, can be reached at 571-272-0925. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

D. Luklan

